AXP® Processing Technology
What is processing?
The purpose of processing is to separate stem cells from the rest of the cord blood, producing a sample that can be used safely and successfully.
- CBR processes cord blood without any unnecessary additives.
- Reducing red blood cells decreases the likelihood of certain complications in future use.
- The United States Food and Drug Administration recommends that prior to cryopreservation, the cord blood unit should be depleted of plasma and red blood cells.75
What processing technology does CBR use?
CBR uses AXP® processing technology when separating out the cell concentration rich in stem cells from your family's cord blood collection for ultimate precision. The AXP AutoXpress® Platform* is FDA-cleared and automated to assist with cGMP (current good manufacturing practice) and cGTP (current good tissue practice) compliance.
- Ensures consistent sterility & quality
- Prevents exposure to environmental pathogens common in manual processes
- Proven ability to recover 99% of cells - 20% higher than processes using Sepax® and Hespan®†
- Repeatable and consistent process, unlike manual systems
- Exact measurements at every step of the process prevents human error
- Fully electronic documentation and quality controls provide complete and accurate records every time
Having more stem cells for treatment has been shown to improve medical outcomes.10>
Additional resources comparing cord blood processing methodsAXP
Reference: Rosenthal J, Brown HL, Harris DT. Biol Blood Marrow Transplant. 2008;14(2). Abstract presented at the 2008 American Society for Blood and Marrow Transplantation (ASBMT) Annual Meeting.Sepax
Reference: Papassavas AC, Gioka V, Chatzistamatiou T, et al. A strategy of splitting individual high volume cord blood units into two half subunits prior to processing increases the recovery of cells and facilitates ex vivo expansion of the infused hematopoietic progenitor cells in adults. Int J Lab Hematol. 2008;30(2):124-132.Hespan
Reference: Kurtzberg J, Cairo MS, Fraser JK, et al. Results of the cord blood transplantation (COBLT) study unrelated donor banking program. Transfusion. 2005;45(6):842-855.
† All registered trademarks are the property of their respective owners.
‡ XpressTRAK software is a registered trademark of ThermoGenesis Corp.